CRL Charles River Laboratories International Inc

  1. Stocks
  2. Healthcare
  3. NYSE: CRL

Price (delayed)

$194.12

Market cap

$9.94B

P/E Ratio

19.89

Dividend/share

N/A

EPS

$9.76

Enterprise value

$12.9B

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights
The price to earnings (P/E) is 41% lower than the 5-year quarterly average of 33.6 and 13% lower than the last 4 quarters average of 22.8
The equity is up by 19% year-on-year and by 4.4% since the previous quarter
Charles River Laboratories International's debt has increased by 7% YoY and by 2.1% QoQ
The gross margin has declined by 2.4% year-on-year
Sector: Healthcare
Industry: Diagnostics & Research
Website: https://www.criver.com/
Peers: RGEN SCYX TMO

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
51.18M
Market cap
$9.94B
Enterprise value
$12.9B
Valuations
Price to earnings (P/E)
19.89
Price to book (P/B)
3.18
Price to sales (P/S)
2.42
EV/EBIT
17.85
EV/EBITDA
12.54
EV/Sales
3.15
Earnings
Revenue
$4.09B
EBIT
$722.42M
EBITDA
$1.03B
Free cash flow
$275.25M
Per share
EPS
$9.76
Free cash flow per share
$5.39
Book value per share
$60.97
Revenue per share
$80.07
TBVPS
$75.15
Balance sheet
Total assets
$7.7B
Total liabilities
$4.54B
Debt
$3.16B
Equity
$3.11B
Working capital
$466.96M
Liquidity
Debt to equity
1.02
Current ratio
1.48
Quick ratio
1.01
Net debt/EBITDA
2.88
Margins
EBITDA margin
25.1%
Gross margin
36.7%
Net margin
12.1%
Operating margin
16.4%
Efficiency
Return on assets
6.6%
Return on equity
17.5%
Return on invested capital
12.6%
Return on capital employed
10.8%
Return on sales
17.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
-0.4%
1 week
-2.12%
1 month
3.8%
1 year
-15.68%
YTD
-10.91%
QTD
-3.82%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$4.09B
Gross profit
$1.5B
Operating income
$670.09M
Net income
$496.34M
Gross margin
36.7%
Net margin
12.1%
The net income has increased by 17% year-on-year and by 2.1% since the previous quarter
CRL's revenue is up by 13% year-on-year and by 2.9% since the previous quarter
Charles River Laboratories International's gross profit has increased by 10% YoY and by 2.8% QoQ
CRL's operating income is up by 9% YoY and by 2.9% QoQ

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
CRL P/E details
P/E
19.89
P/B
3.18
P/S
2.42
EV/EBIT
17.85
EV/EBITDA
12.54
EV/Sales
3.15
The price to earnings (P/E) is 41% lower than the 5-year quarterly average of 33.6 and 13% lower than the last 4 quarters average of 22.8
The EPS rose by 16% YoY
The price to book (P/B) is 39% lower than the 5-year quarterly average of 5.2 and 16% lower than the last 4 quarters average of 3.8
The equity is up by 19% year-on-year and by 4.4% since the previous quarter
The P/S is 31% lower than the 5-year quarterly average of 3.5 and 10% lower than the last 4 quarters average of 2.7
CRL's revenue is up by 13% year-on-year and by 2.9% since the previous quarter

Efficiency

How efficient is Charles River Laboratories International business performance
The ROS rose by 13% YoY and by 4.1% QoQ
The company's return on invested capital rose by 11% YoY and by 3.3% QoQ
The company's return on assets rose by 8% YoY
The ROE has grown by 2.3% YoY but it has contracted by 2.2% from the previous quarter

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 69% higher than its total liabilities
Charles River Laboratories International's current ratio has increased by 12% from the previous quarter and by 10% YoY
The quick ratio is up by 12% since the previous quarter and by 6% year-on-year
The equity is up by 19% year-on-year and by 4.4% since the previous quarter
Charles River Laboratories International's debt to equity has decreased by 10% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.